FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer with EGFR Exon 19 Deletions or L858R Mutations By Ogkologos - October 29, 2024 1847 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MARIPOSA-2 study Source RELATED ARTICLESMORE FROM AUTHOR High HPV Vaccination Coverage in England Associated with a Substantial Reduction in Cervical Cancer Mortality FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions MOST POPULAR Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not... May 8, 2023 FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung... July 25, 2025 A Message from the ESMO President March 17, 2020 Cancer Rehabilitation Starts at Diagnosis July 6, 2021 Load more HOT NEWS Nivolumab Improves Survival for Some Patients with Advanced Stomach Cancer Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in... For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free.
